Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

NCT04888507 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG: Pozelimab
DRUG: Cemdisiran

Sponsor

Regeneron Pharmaceuticals